SCYNEXIS (NASDAQ:SCYX – Get Free Report) was downgraded by equities researchers at StockNews.com from a “buy” rating to a “hold” rating in a research report issued to clients and investors on Wednesday.
SCYX has been the topic of several other research reports. TheStreet upgraded SCYNEXIS from a “d-” rating to a “c+” rating in a research report on Wednesday, August 23rd. Cantor Fitzgerald reissued an “overweight” rating and set a $15.00 target price on shares of SCYNEXIS in a research note on Tuesday, August 15th. One equities research analyst has rated the stock with a hold rating and three have given a buy rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $12.25.
SCYNEXIS Stock Down 4.8 %
SCYNEXIS (NASDAQ:SCYX – Get Free Report) last issued its quarterly earnings data on Monday, August 14th. The company reported $2.46 EPS for the quarter, beating the consensus estimate of $1.03 by $1.43. SCYNEXIS had a return on equity of 425.97% and a net margin of 53.14%. The company had revenue of $131.45 million for the quarter, compared to analyst estimates of $91.50 million. As a group, sell-side analysts anticipate that SCYNEXIS will post 2.65 earnings per share for the current year.
Institutional Trading of SCYNEXIS
Large investors have recently made changes to their positions in the company. Citigroup Inc. acquired a new stake in shares of SCYNEXIS in the 1st quarter valued at about $26,000. Spire Wealth Management acquired a new stake in shares of SCYNEXIS in the 1st quarter valued at about $26,000. Schonfeld Strategic Advisors LLC acquired a new stake in shares of SCYNEXIS in the 2nd quarter valued at about $33,000. Belvedere Trading LLC acquired a new stake in SCYNEXIS during the 1st quarter worth approximately $34,000. Finally, Vontobel Holding Ltd. acquired a new stake in SCYNEXIS during the 2nd quarter worth approximately $34,000. 49.87% of the stock is owned by institutional investors and hedge funds.
SCYNEXIS, Inc, a biotechnology company, develops products for the treatment of fungal infections in the United States. It offers BREXAFEMME for the treatment of vulvovaginal candidiasis (VVC) and recurrent VVC. The company's lead product candidate is Ibrexafungerp, an intravenous drug for the treatment of various fungal infections, including invasive candidiasis, refractory invasive fungal infections, invasive aspergillosis, VVC, and recurrent VVC.
- Five stocks we like better than SCYNEXIS
- How to Invest in the FAANG Stocks
- Amazon, Target, Walmart in a race for fastest delivery
- How to Invest in Canada for Beginners
- Palo Alto Networks: the one security stock to rule them all
- How to Invest in Grocery Stores
- Is it time to buy the dip in Walmart shares?
Receive News & Ratings for SCYNEXIS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SCYNEXIS and related companies with MarketBeat.com's FREE daily email newsletter.